UBS raised the firm’s price target on GoodRx to $8 from $5 and keeps a Neutral rating on the shares. The positive 2024 guidance surprise and the announcement of a $450M share repurchase authorization should support shares at current levels, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GDRX:
